Please enable JavaScript to continue using this application.

Compare $ABEO vs $CATX | Chartloom

Compare

$ABEO vs $CATX

Abeona Therapeutics Inc · Perspective Therapeutics Inc

ABEO

Abeona Therapeutics Inc

CATX

Perspective Therapeutics Inc

Compare $ABEO vs $CATX

Comparing Abeona Therapeutics Inc and Perspective Therapeutics Inc

ABEOAbeona Therapeutics Inc

CATXPerspective Therapeutics Inc

ABEOAbeona Therapeutics Inc

Market cap

$282M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.20x

Rev growth (TTM)

6280.0%

YTD performance

-7.0%

52W performance

-10.8%

FCF yield

-29.0%

CATXPerspective Therapeutics Inc

Market cap

$303M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-66.9%

YTD performance

-4.7%

52W performance

-31.1%

FCF yield

-40.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ABEO

CATX

Detailed metrics comparison

ABEO

Abeona Therapeutics Inc

CATX

Perspective Therapeutics Inc

Market Cap

ABEO$282M

CATX$303M

Enterprise Value

ABEO$240M

CATX$256M

Price

ABEO$4.94

CATX$2.66

P/E Ratio

ABEON/A

CATXN/A

P/S Ratio

ABEO11.03x

CATX741.74x

EV/Sales

ABEO9.42x

CATX627.10x

EV/EBITDA

ABEO3.95x

CATX0.00x

P/B Ratio

ABEO2.25x

CATX0.97x

P/FCF Ratio

ABEON/A

CATXN/A

EV/FCF

ABEO-2.95x

CATX-2.11x

PEG Ratio

ABEON/A

CATXN/A

Forward P/E (NTM)

ABEON/A

CATXN/A

Forward P/S (NTM)

ABEO3.20x

CATXN/A

Revenue (TTM)

ABEO$26M

CATX$409K

Revenue Growth (YoY)

ABEO6280.0%

CATX-66.9%

Forward Rev Growth

ABEO131.0%

CATX32.5%

Gross Margin (TTM)

ABEO67.1%

CATX23.0%

Operating Margin (TTM)

ABEO0.0%

CATX0.0%

EBITDA Margin (TTM)

ABEO-316.6%

CATX-29628.1%

Net Margin (TTM)

ABEO-246.4%

CATX-28468.0%

FCF Margin (TTM)

ABEO-319.5%

CATX-29657.2%

Net Income (TTM)

ABEO$-63M

CATX$-116M

FCF (TTM)

ABEO$-82M

CATX$-121M

EPS (TTM)

ABEO-$1.10

CATX-$0.97

ROE (TTM)

ABEO-4169.0%

CATX-4156.0%

ROA (TTM)

ABEO-3036.0%

CATX-3413.0%

ROIC (TTM)

ABEO-3719.0%

CATX-4132.0%

Cash

ABEO$56M

CATX$48M

Debt

ABEO$15M

CATX$2M

Net Cash/Debt

ABEO$41M

CATX$47M

Current Ratio (TTM)

ABEO6.63x

CATX6.61x

Quick Ratio (TTM)

ABEO6.32x

CATX6.49x

Debt/Equity (TTM)

ABEO0.12x

CATX0.00x

Debt/Assets (TTM)

ABEO0.0%

CATX0.0%

Interest Coverage (TTM)

ABEON/A

CATXN/A

Net Debt/EBITDA (TTM)

ABEO0.00x

CATX0.00x

Beta

ABEO1.45

CATX1.87

52W Performance

ABEO-10.8%

CATX-31.1%

YTD Performance

ABEO-7.0%

CATX-4.7%

% from 52W High

ABEO-35.4%

CATX-56.8%

% from 52W Low

ABEO23.5%

CATX35.7%

Asset Turnover (TTM)

ABEO0.13x

CATX0.00x

FCF Yield (TTM)

ABEO-29.0%

CATX-40.0%

Earnings Yield (TTM)

ABEO-22.3%

CATX-38.4%

Dividend Yield (TTM)

ABEON/A

CATXN/A

Rule of 40

ABEO5,960.5

CATX-29,724.1

EV/GP/RG

ABEO0.04

CATX22.31

Ticker research

View ABEO research View CATX research

Metric	ABEO Abeona Therapeutics Inc	CATX Perspective Therapeutics Inc
Market & Valuation
Market Cap	$282M	$303M
Enterprise Value	$240M	$256M
Price	$4.94	$2.66
P/E Ratio	N/A	N/A
P/S Ratio	11.03x	741.74x
EV/Sales	9.42x	627.10x
EV/EBITDA	3.95x	0.00x
P/B Ratio	2.25x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.95x	-2.11x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.20x	N/A
Revenue & Growth
Revenue (TTM)	$26M	$409K
Revenue Growth (YoY)	6280.0%	-66.9%
Forward Rev Growth	131.0%	32.5%
Profitability
Gross Margin (TTM)	67.1%	23.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-316.6%	-29628.1%
Net Margin (TTM)	-246.4%	-28468.0%
FCF Margin (TTM)	-319.5%	-29657.2%
Net Income (TTM)	$-63M	$-116M
FCF (TTM)	$-82M	$-121M
EPS (TTM)	-$1.10	-$0.97
ROE (TTM)	-4169.0%	-4156.0%
ROA (TTM)	-3036.0%	-3413.0%
ROIC (TTM)	-3719.0%	-4132.0%
Financial Health
Cash	$56M	$48M
Debt	$15M	$2M
Net Cash/Debt	$41M	$47M
Current Ratio (TTM)	6.63x	6.61x
Quick Ratio (TTM)	6.32x	6.49x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.45	1.87
52W Performance	-10.8%	-31.1%
YTD Performance	-7.0%	-4.7%
% from 52W High	-35.4%	-56.8%
% from 52W Low	23.5%	35.7%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.00x
FCF Yield (TTM)	-29.0%	-40.0%
Earnings Yield (TTM)	-22.3%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,960.5	-29,724.1
EV/GP/RG	0.04	22.31
Ticker research	View ABEO research	View CATX research

Valuation

P/S Ratio

ABEO

11.03x

CATX

741.74x

EV/FCF

ABEO

-2.95x

CATX

-2.11x

Growth & revenue

Revenue Growth TTM

ABEO

6280.0%

CATX

-66.9%

Forward Revenue Growth

ABEO

131.0%

CATX

32.5%

Profitability & performance

Gross Margin

ABEO

67.1%

CATX

23.0%

ROE

CATX

-4156.0%

ABEO

-4169.0%

FCF Yield %

ABEO

-29.0%

CATX

-40.0%

52-Week Performance

ABEO

-10.8%

CATX

-31.1%

Detailed metrics comparison

ABEO

Abeona Therapeutics Inc

CATX

Perspective Therapeutics Inc

Market Cap

ABEO$282M

CATX$303M

Enterprise Value

ABEO$240M

CATX$256M

Price

ABEO$4.94

CATX$2.66

P/E Ratio

ABEON/A

CATXN/A

P/S Ratio

ABEO11.03x

CATX741.74x

EV/Sales

ABEO9.42x

CATX627.10x

EV/EBITDA

ABEO3.95x

CATX0.00x

P/B Ratio

ABEO2.25x

CATX0.97x

P/FCF Ratio

ABEON/A

CATXN/A

EV/FCF

ABEO-2.95x

CATX-2.11x

PEG Ratio

ABEON/A

CATXN/A

Forward P/E (NTM)

ABEON/A

CATXN/A

Forward P/S (NTM)

ABEO3.20x

CATXN/A

Revenue (TTM)

ABEO$26M

CATX$409K

Revenue Growth (YoY)

ABEO6280.0%

CATX-66.9%

Forward Rev Growth

ABEO131.0%

CATX32.5%

Gross Margin (TTM)

ABEO67.1%

CATX23.0%

Operating Margin (TTM)

ABEO0.0%

CATX0.0%

EBITDA Margin (TTM)

ABEO-316.6%

CATX-29628.1%

Net Margin (TTM)

ABEO-246.4%

CATX-28468.0%

FCF Margin (TTM)

ABEO-319.5%

CATX-29657.2%

Net Income (TTM)

ABEO$-63M

CATX$-116M

FCF (TTM)

ABEO$-82M

CATX$-121M

EPS (TTM)

ABEO-$1.10

CATX-$0.97

ROE (TTM)

ABEO-4169.0%

CATX-4156.0%

ROA (TTM)

ABEO-3036.0%

CATX-3413.0%

ROIC (TTM)

ABEO-3719.0%

CATX-4132.0%

Cash

ABEO$56M

CATX$48M

Debt

ABEO$15M

CATX$2M

Net Cash/Debt

ABEO$41M

CATX$47M

Current Ratio (TTM)

ABEO6.63x

CATX6.61x

Quick Ratio (TTM)

ABEO6.32x

CATX6.49x

Debt/Equity (TTM)

ABEO0.12x

CATX0.00x

Debt/Assets (TTM)

ABEO0.0%

CATX0.0%

Interest Coverage (TTM)

ABEON/A

CATXN/A

Net Debt/EBITDA (TTM)

ABEO0.00x

CATX0.00x

Beta

ABEO1.45

CATX1.87

52W Performance

ABEO-10.8%

CATX-31.1%

YTD Performance

ABEO-7.0%

CATX-4.7%

% from 52W High

ABEO-35.4%

CATX-56.8%

% from 52W Low

ABEO23.5%

CATX35.7%

Asset Turnover (TTM)

ABEO0.13x

CATX0.00x

FCF Yield (TTM)

ABEO-29.0%

CATX-40.0%

Earnings Yield (TTM)

ABEO-22.3%

CATX-38.4%

Dividend Yield (TTM)

ABEON/A

CATXN/A

Rule of 40

ABEO5,960.5

CATX-29,724.1

EV/GP/RG

ABEO0.04

CATX22.31

Ticker research

View ABEO research View CATX research

Metric	ABEO Abeona Therapeutics Inc	CATX Perspective Therapeutics Inc
Market & Valuation
Market Cap	$282M	$303M
Enterprise Value	$240M	$256M
Price	$4.94	$2.66
P/E Ratio	N/A	N/A
P/S Ratio	11.03x	741.74x
EV/Sales	9.42x	627.10x
EV/EBITDA	3.95x	0.00x
P/B Ratio	2.25x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.95x	-2.11x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.20x	N/A
Revenue & Growth
Revenue (TTM)	$26M	$409K
Revenue Growth (YoY)	6280.0%	-66.9%
Forward Rev Growth	131.0%	32.5%
Profitability
Gross Margin (TTM)	67.1%	23.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-316.6%	-29628.1%
Net Margin (TTM)	-246.4%	-28468.0%
FCF Margin (TTM)	-319.5%	-29657.2%
Net Income (TTM)	$-63M	$-116M
FCF (TTM)	$-82M	$-121M
EPS (TTM)	-$1.10	-$0.97
ROE (TTM)	-4169.0%	-4156.0%
ROA (TTM)	-3036.0%	-3413.0%
ROIC (TTM)	-3719.0%	-4132.0%
Financial Health
Cash	$56M	$48M
Debt	$15M	$2M
Net Cash/Debt	$41M	$47M
Current Ratio (TTM)	6.63x	6.61x
Quick Ratio (TTM)	6.32x	6.49x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.45	1.87
52W Performance	-10.8%	-31.1%
YTD Performance	-7.0%	-4.7%
% from 52W High	-35.4%	-56.8%
% from 52W Low	23.5%	35.7%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.00x
FCF Yield (TTM)	-29.0%	-40.0%
Earnings Yield (TTM)	-22.3%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,960.5	-29,724.1
EV/GP/RG	0.04	22.31
Ticker research	View ABEO research	View CATX research